245 related articles for article (PubMed ID: 32859216)
1. Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study.
Zheng Y; Wu J; Ding C; Xu K; Yang S; Li L
Virol J; 2020 Aug; 17(1):132. PubMed ID: 32859216
[TBL] [Abstract][Full Text] [Related]
2. Assessing the impact of comorbid type 2 diabetes mellitus on the disease burden of chronic hepatitis B virus infection and its complications in China from 2006 to 2030: a modeling study.
Xie J; Wang X; Wang X; Li J; Jie Y; Hao Y; Gu J
Glob Health Res Policy; 2024 Jan; 9(1):5. PubMed ID: 38246986
[TBL] [Abstract][Full Text] [Related]
3. Chronic hepatitis B virus infection in Asian countries.
Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
[TBL] [Abstract][Full Text] [Related]
4. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain.
Idris BI; Brosa M; Richardus JH; Esteban R; Schalm SW; Buti M
Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):320-6. PubMed ID: 18334876
[TBL] [Abstract][Full Text] [Related]
5. [Development of Markov models for economics evaluation of strategies on hepatitis B vaccination and population-based antiviral treatment in China].
Yang PC; Zhang SX; Sun PP; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):845-851. PubMed ID: 28738454
[No Abstract] [Full Text] [Related]
6. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
[TBL] [Abstract][Full Text] [Related]
7. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort.
Zhu L; Zhai X; Wang Q; Jiang J; Peng H; Song C; Ge Z; Qian J; Zhou M; Zhou Y; Xu J; Liu H; Hang D; Hu Z; Shen H; Zhu F
J Viral Hepat; 2018 Dec; 25(12):1588-1598. PubMed ID: 30112835
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation.
Zhang S; Wang C; Liu B; Lu QB; Shang J; Zhou Y; Jia J; Xu X; Rao H; Han B; Zhao T; Chen L; Xie M; Cui J; Du J; Zeng J; Huang N; Liu Y; Zhang L; Zhuang H; Cui F
Lancet Reg Health West Pac; 2023 Jun; 35():100738. PubMed ID: 37424693
[TBL] [Abstract][Full Text] [Related]
9. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
10. The current and future burden of hepatitis B in Switzerland: a modelling study.
Negro F; Müllhaupt B; Semela D; Blach S; Bruggmann P; De Gottardi A; Dufour JF; Fraga M; Galante A; Razavi H; Vieira Barbosa J; Razavi-Shearer D
Swiss Med Wkly; 2023 Jun; 153():40086. PubMed ID: 37410921
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
Chan HL; Thompson A; Martinot-Peignoux M; Piratvisuth T; Cornberg M; Brunetto MR; Tillmann HL; Kao JH; Jia JD; Wedemeyer H; Locarnini S; Janssen HL; Marcellin P
J Hepatol; 2011 Nov; 55(5):1121-31. PubMed ID: 21718667
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
13. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
[TBL] [Abstract][Full Text] [Related]
14. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
15. Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model.
Zu J; Li M; Zhuang G; Liang P; Cui F; Wang F; Zheng H; Liang X
Medicine (Baltimore); 2018 Apr; 97(16):e0484. PubMed ID: 29668627
[TBL] [Abstract][Full Text] [Related]
16. Chronic hepatitis B in Asia-new insights from the past decade.
Chan HL; Jia J
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():131-7. PubMed ID: 21199524
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of acute hepatitis E super-infections on chronic hepatitis B.
Chen C; Zhang SY; Zhang DD; Li XY; Zhang YL; Li WX; Yan JJ; Wang M; Xun JN; Lu C; Ling Y; Huang YX; Chen L
World J Gastroenterol; 2016 Dec; 22(47):10388-10397. PubMed ID: 28058019
[TBL] [Abstract][Full Text] [Related]
18. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia.
Sanai FM; Alghamdi M; Dugan E; Alalwan A; Al-Hamoudi W; Abaalkhail F; AlMasri N; Razavi-Shearer D; Razavi H; Schmelzer J; Alfaleh FZ
J Infect Public Health; 2020 Nov; 13(11):1715-1723. PubMed ID: 32988769
[TBL] [Abstract][Full Text] [Related]
19. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
Chen CH; Lu SN; Hung CH; Wang JH; Hu TH; Changchien CS; Lee CM
J Hepatol; 2014 Sep; 61(3):515-22. PubMed ID: 24798617
[TBL] [Abstract][Full Text] [Related]
20. How to control highly endemic hepatitis B in Asia.
Shan S; Cui F; Jia J
Liver Int; 2018 Feb; 38 Suppl 1():122-125. PubMed ID: 29427490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
